09:57 AM EDT, 10/02/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Wednesday results from a study showed its Erleada, or apalutamide, provided a 'statistically significant overall survival benefit' at 24 months compared with enzalutamide in patients with metastatic castration-sensitive prostate cancer.

Johnson & Johnson ( JNJ ) said the head-to-head study of apalutamide and enzalutamide

included nearly 4,000 patients, and demonstrated apalutamide reduced the risk of death by 23% at 24 months compared with enzalutamide.

Longer-term studies are needed to fully evaluate the therapeutic effects of both treatements, the company added.

Price: 161.35, Change: -0.64, Percent Change: -0.40